[시장보고서]신경조절 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

신경조절 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Neuromodulation Devices Market Size, Share & Trends Analysis Report By Product, By Application, By End-use, By Region, And Segment Forecasts, 2026 - 2033

상품코드 : 1908164

리서치사 : Grand View Research

발행일 : 2025년 12월

페이지 정보 : 영문 120 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,615,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,062,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,958,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

신경조절 기기 시장 개요

세계의 신경조절 기기 시장 규모는 2025년에 63억 7,000만 달러로 추정되며, 2033년에 139억 3,000만 달러에 달할 것으로 예측됩니다.

2026년부터 2033년까지 CAGR 10.35%로 성장할 것으로 예상됩니다. 이러한 장치에 대한 정부 R&D 자금의 증가, 신경 질환의 유병률 증가, 기술 발전이 시장 성장을 주도하고 있습니다.

예를 들어, 파킨슨병 재단에 따르면 미국에서는 약 100만 명이 파킨슨병을 앓고 있으며, 2030년까지 120만 명으로 늘어날 것으로 예측하고 있습니다. 신경질환의 발생률은 증가 추세에 있으며, 신경조절기기를 포함한 혁신적인 치료 솔루션에 대한 수요가 증가하고 있습니다. 예를 들어, 세계보건기구(WHO)의 2024년 2월 기준 자료에 따르면, 간질 진단을 받은 환자 수는 약 500만 명, 인구 10만 명당 약 49명에 해당합니다. 또한, 파킨슨병, 본태성 진전, 근긴장이상증, 난치성 간질 등의 질환은 뇌심부자극술(DBS) 및 기타 이식형 신경자극시스템과 같은 기술을 통해 치료하는 사례가 증가하고 있습니다. 따라서 이러한 질병의 유병률 증가는 고급 신경 조절 기기에 대한 수요를 크게 증가시키고 있습니다.

기술 발전, 특히 차세대 체내 이식형 신경조절기기의 지속적인 도입은 신경조절기기 시장의 성장을 견인하는 주요 요인입니다. 소형화된 이식 시스템, 폐쇄 루프 자극, AI 기반 프로그래밍, 무선 또는 충전식 플랫폼과 같은 혁신은 기기의 정확성, 환자의 편안함, 장기적인 치료 결과를 크게 향상시키고 있습니다. 신제품 출시로 임상 적응증도 확대되어 만성 통증, 운동장애, 간질, 우울증, 신흥 신경정신질환 등에 대한 치료효과가 향상되고 있습니다. 기업들이 장수명 배터리, 개인화된 자극 알고리즘, 원격 모니터링을 위한 향상된 연결성을 갖춘 기기를 도입함에 따라 임상의와 환자 모두 이러한 솔루션을 더 빠른 속도로 채택하고 있으며, 이는 시장 확장을 지원하고 전 세계가 첨단 신경 조절 치료로 전환하는 것을 가속화하고 있습니다.

지역별 대시보드
시장 규모와 동향 분석, 2021-2033년
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 스웨덴
- 덴마크
- 노르웨이
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제8장 경쟁 구도

주요 시장 진입 기업의 최근 동향과 영향 분석
기업 분류
2025년의 기업 점유율 분석
기업 히트맵 분석
전략 매핑
- 사업 확대
- 인수합병
- 제휴·협업
- 신제품 발매
- 연구개발
- 기업 개요
- Abbott(St. Jude Medical)
- Medtronic
- Boston Scientific Corporation
- Aleva Neurotherapeutics
- Nexstim
- LivaNova PLC
- Neuropace Inc.
- Mainstay Medical
- Saluda Medical Pty Ltd
- Biotronik
- electroCore, Inc.
- MicroTransponder Inc.
- tVNS Technologies GmbH
- Laborie

KSM

영문 목차

영문목차

Neuromodulation Devices Market Summary

The global neuromodulation devices market size was estimated at USD 6.37 billion in 2025 and is projected to reach USD 13.93 billion by 2033, growing at a CAGR of 10.35% from 2026 to 2033. The rising government funding for R&D activities in these devices, increasing prevalence of neurological disorders and technological advancements in these devices are driving the market growth.

For instance, according to the Parkinson's Foundation, around 1 million people are living with Parkinson's disease in the U.S., which is further expected to increase to 1.2 million by 2030. The incidence of neurological disorders is on the rise, leading to an increased need for innovative treatment solutions, including neuromodulation devices. For instance, according to the World Health Organization (WHO) in February 2024, around 5 million people are diagnosed with epilepsy, which is around 49 people per 100,000 population. Moreover, conditions such as Parkinson's disease, essential tremor, dystonia, and medically refractory epilepsy are increasingly being addressed through techniques such as Deep Brain Stimulation (DBS) and other implantable neurostimulation systems. Thus, the increasing prevalence of these conditions significantly increases the demand for advanced neuromodulation devices.

Technological advancements, particularly the continuous introduction of next-generation internal neuromodulation devices, are a major driving force behind the growth of the neuromodulation devices market. Innovations such as miniaturized implantable systems, closed-loop stimulation, AI-driven programming, and wireless or rechargeable platforms are significantly improving device precision, patient comfort, and long-term therapy outcomes. New product launches also expand clinical indications, enabling treatment of chronic pain, movement disorders, epilepsy, depression, and emerging neuropsychiatric conditions with greater efficacy. As companies introduce devices with longer battery life, personalized stimulation algorithms, and enhanced connectivity for remote monitoring, both clinicians and patients are adopting these solutions at a faster pace, supporting broader market expansion and accelerating the global shift toward advanced neuromodulation therapies.

Global Neuromodulation Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global neuromodulation devices market report on the basis of product, application, end-use, and region:

Product Outlook (Revenue, USD Million, 2021 - 2033)
Spinal Cord Stimulators
Deep Brain Stimulators
Sacral Nerve Stimulators
Vagus Nerve Stimulators
Gastric Electrical Stimulation
Others
Application Outlook (Revenue, USD Million, 2021 - 2033)
Parkinson's Disease
Chronic Pain
Migraine
Epilepsy
Tremor
Depression
Urinary & Faecal Incontinence
Others
End-use Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals & Ambulatory Surgery Centers (ASC)
Clinics & Physiotherapy Centers
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
- 1.1.1. Product
- 1.1.2. Application
- 1.1.3. End Use
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
1.5. Details of primary research
- 1.5.1. Data for primary interviews in North America
- 1.5.2. Data for primary interviews in Europe
- 1.5.3. Data for primary interviews in Asia Pacific
- 1.5.4. Data for primary interviews in Latin America
- 1.5.5. Data for Primary interviews in MEA
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
  - 1.7.1.1. Approach 1: Commodity flow approach
- 1.7.2. Volume price analysis (Model 2)
  - 1.7.2.1. Approach 2: Volume price analysis
1.8. Research Scope and Assumptions
- 1.8.1. List of Secondary Sources
- 1.8.2. List of Primary Sources
- 1.8.3. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Neuromodulation Devices Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Drivers Analysis
  - 3.2.1.1. Government funding for research and development
  - 3.2.1.2. Technological advancements in neuromodulation devices
  - 3.2.1.3. Increasing prevalence of neurological disorders
  - 3.2.1.4. Growing reimbursement coverage
  - 3.2.1.5. Expanding applications
- 3.2.2. Market Restraints Analysis
  - 3.2.2.1. Complex regulatory framework
  - 3.2.2.2. Surgery-associated risk
- 3.2.3. Market Opportunity Analysis
  - 3.2.3.1. Increasing number of clinical trials and studies
- 3.2.4. Market Challenge Analysis
  - 3.2.4.1. Product recalls
  - 3.2.4.2. Alternatives to neuromodulation systems
3.3. Neuromodulation Devices Market Analysis Tools
- 3.3.1. Porter's Analysis
  - 3.3.1.1. Bargaining power of the suppliers
  - 3.3.1.2. Bargaining power of the buyers
  - 3.3.1.3. Threats of substitution
  - 3.3.1.4. Threats from new entrants
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Economic and Social landscape
  - 3.3.2.3. Technological landscape
  - 3.3.2.4. Environmental landscape
  - 3.3.2.5. Legal landscape

Chapter 4. Neuromodulation Devices Market: Product Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global Neuromodulation Devices Market: Product Movement Analysis, 2025 & 2033 (USD Million)
4.3. Global Neuromodulation Devices Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Spinal Cord Stimulators
- 4.4.1. Spinal cord stimulators market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.5. Deep Brain Stimulators
- 4.5.1. Deep brain stimulators market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.6. Sacral Nerve Stimulators
- 4.6.1. Sacral nerve stimulators market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.7. Vagus Nerve Stimulators
- 4.7.1. Vagus nerve stimulators market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.8. Gastric Electrical Stimulation
- 4.8.1. Gastric electrical stimulation market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.9. Others
- 4.9.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Neuromodulation Devices Market: Application Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global Neuromodulation Devices Market: Application Movement Analysis, 2025 & 2033 (USD Million)
5.3. Global Neuromodulation Devices Market Size & Trend Analysis, by Application 2021 to 2033 (USD Million)
5.4. Parkinson's Disease
- 5.4.1. Parkinson's disease market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.5. Chronic Pain
- 5.5.1. Chronic pain market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.6. Migraine
- 5.6.1. Migraine market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.7. Epilepsy
- 5.7.1. Epilepsy market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.8. Tremor
- 5.8.1. Tremor market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.9. Depression
- 5.9.1. Depression market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.10. Urinary & Fecal Incontinence
- 5.10.1. Urinary & fecal incontinence market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.11. Others
- 5.11.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Neuromodulation Devices Market: End Use Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global Neuromodulation Devices Market: End Use Movement Analysis, 2025 & 2033 (USD Million)
6.3. Global Neuromodulation Devices Market Size & Trend Analysis, by End Use 2021 to 2033 (USD Million)
6.4. Hospitals & Ambulatory Surgery Centers (ASC)
- 6.4.1. Hospitals & Ambulatory Surgery Centers (ASC) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
6.5. Clinics & Physiotherapy Centers
- 6.5.1. Clinics & physiotherapy centers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
6.6. Others
- 6.6.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Neuromodulation Devices Market: Regional Estimates & Trend Analysis by Product, Application and End Use

7.1. Regional Dashboard
7.2. Market Size and Trend Analysis, 2021 to 2033
7.3. North America
- 7.3.1. North America neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.3.2. U.S.
  - 7.3.2.1. Key country dynamics
  - 7.3.2.2. Competitive scenario
  - 7.3.2.3. Regulatory framework
  - 7.3.2.4. Reimbursement scenario
  - 7.3.2.5. U.S. neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.3.3. Canada
  - 7.3.3.1. Key country dynamics
  - 7.3.3.2. Competitive scenario
  - 7.3.3.3. Regulatory framework
  - 7.3.3.4. Reimbursement scenario
  - 7.3.3.5. Canada neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.3.4. Mexico
  - 7.3.4.1. Key country dynamics
  - 7.3.4.2. Competitive scenario
  - 7.3.4.3. Regulatory framework
  - 7.3.4.4. Reimbursement scenario
  - 7.3.4.5. Mexico neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
7.4. Europe
- 7.4.1. Europe neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.2. UK
  - 7.4.2.1. Key country dynamics
  - 7.4.2.2. Competitive scenario
  - 7.4.2.3. Regulatory framework
  - 7.4.2.4. Reimbursement scenario
  - 7.4.2.5. UK neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Germany
  - 7.4.3.1. Key country dynamics
  - 7.4.3.2. Competitive scenario
  - 7.4.3.3. Regulatory framework
  - 7.4.3.4. Reimbursement scenario
  - 7.4.3.5. Germany neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.4. France
  - 7.4.4.1. Key country dynamics
  - 7.4.4.2. Competitive scenario
  - 7.4.4.3. Regulatory framework
  - 7.4.4.4. Reimbursement scenario
  - 7.4.4.5. France neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.5. Italy
  - 7.4.5.1. Key country dynamics
  - 7.4.5.2. Competitive scenario
  - 7.4.5.3. Regulatory framework
  - 7.4.5.4. Reimbursement scenario
  - 7.4.5.5. Italy neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.6. Spain
  - 7.4.6.1. Key country dynamics
  - 7.4.6.2. Competitive scenario
  - 7.4.6.3. Regulatory framework
  - 7.4.6.4. Reimbursement scenario
  - 7.4.6.5. Spain neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.7. Sweden
  - 7.4.7.1. Key country dynamics
  - 7.4.7.2. Competitive scenario
  - 7.4.7.3. Regulatory framework
  - 7.4.7.4. Reimbursement scenario
  - 7.4.7.5. Sweden neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.8. Denmark
  - 7.4.8.1. Key country dynamics
  - 7.4.8.2. Competitive scenario
  - 7.4.8.3. Regulatory framework
  - 7.4.8.4. Reimbursement scenario
  - 7.4.8.5. Denmark neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.9. Norway
  - 7.4.9.1. Key country dynamics
  - 7.4.9.2. Competitive scenario
  - 7.4.9.3. Regulatory framework
  - 7.4.9.4. Reimbursement scenario
  - 7.4.9.5. Norway neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
7.5. Asia Pacific
- 7.5.1. Asia Pacific neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5.2. China
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Competitive scenario
  - 7.5.2.3. Regulatory framework
  - 7.5.2.4. Reimbursement scenario
  - 7.5.2.5. China neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Japan
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Competitive scenario
  - 7.5.3.3. Regulatory framework
  - 7.5.3.4. Reimbursement scenario
  - 7.5.3.5. Japan neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5.4. India
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Competitive scenario
  - 7.5.4.3. Regulatory framework
  - 7.5.4.4. Reimbursement scenario
  - 7.5.4.5. India neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5.5. South Korea
  - 7.5.5.1. Key country dynamics
  - 7.5.5.2. Competitive scenario
  - 7.5.5.3. Regulatory framework
  - 7.5.5.4. Reimbursement scenario
  - 7.5.5.5. South Korea neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Australia
  - 7.5.6.1. Key country dynamics
  - 7.5.6.2. Competitive scenario
  - 7.5.6.3. Regulatory framework
  - 7.5.6.4. Reimbursement scenario
  - 7.5.6.5. Australia neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Thailand
  - 7.5.7.1. Key country dynamics
  - 7.5.7.2. Competitive scenario
  - 7.5.7.3. Regulatory framework
  - 7.5.7.4. Reimbursement scenario
  - 7.5.7.5. Thailand neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
7.6. Latin America
- 7.6.1. Latin America neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Brazil
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Competitive scenario
  - 7.6.2.3. Regulatory framework
  - 7.6.2.4. Reimbursement scenario
  - 7.6.2.5. Brazil neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.6.3. Argentina
  - 7.6.3.1. Key country dynamics
  - 7.6.3.2. Competitive scenario
  - 7.6.3.3. Regulatory framework
  - 7.6.3.4. Reimbursement scenario
  - 7.6.3.5. Argentina neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
7.7. Middle East and Africa
- 7.7.1. Middle East and Africa neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.7.2. South Africa
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Competitive scenario
  - 7.7.2.3. Regulatory framework
  - 7.7.2.4. Reimbursement scenario
  - 7.7.2.5. South Africa neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Saudi Arabia
  - 7.7.3.1. Key country dynamics
  - 7.7.3.2. Competitive scenario
  - 7.7.3.3. Regulatory framework
  - 7.7.3.4. Reimbursement scenario
  - 7.7.3.5. Saudi Arabia neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.7.4. UAE
  - 7.7.4.1. Key country dynamics
  - 7.7.4.2. Competitive scenario
  - 7.7.4.3. Regulatory framework
  - 7.7.4.4. Reimbursement scenario
  - 7.7.4.5. UAE neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.7.5. Kuwait
  - 7.7.5.1. Key country dynamics
  - 7.7.5.2. Competitive scenario
  - 7.7.5.3. Regulatory framework
  - 7.7.5.4. Reimbursement scenario
  - 7.7.5.5. Kuwait neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Market Share Analysis, 2025
8.4. Company Heat Map Analysis
8.5. Strategy Mapping
- 8.5.1. Expansion
- 8.5.2. Mergers & Acquisition
- 8.5.3. Partnerships & Collaborations
- 8.5.4. New Product Launches
- 8.5.5. Research And Development
- 8.5.6. Company Profiles
- 8.5.7. Abbott (St. Jude Medical)
  - 8.5.7.1. Company overview
  - 8.5.7.2. Financial performance
  - 8.5.7.3. Product Benchmarking
  - 8.5.7.4. Strategic initiatives
- 8.5.8. Medtronic
  - 8.5.8.1. Company overview
  - 8.5.8.2. Financial performance
  - 8.5.8.3. Product Benchmarking
  - 8.5.8.4. Strategic initiatives
- 8.5.9. Boston Scientific Corporation
  - 8.5.9.1. Company overview
  - 8.5.9.2. Financial performance
  - 8.5.9.3. Product Benchmarking
  - 8.5.9.4. Strategic initiatives
- 8.5.10. Aleva Neurotherapeutics
  - 8.5.10.1. Company overview
  - 8.5.10.2. Financial performance
  - 8.5.10.3. Product Benchmarking
  - 8.5.10.4. Strategic initiatives
- 8.5.11. Nexstim
  - 8.5.11.1. Company overview
  - 8.5.11.2. Financial performance
  - 8.5.11.3. Product Benchmarking
  - 8.5.11.4. Strategic initiatives
- 8.5.12. LivaNova PLC
  - 8.5.12.1. Company overview
  - 8.5.12.2. Financial performance
  - 8.5.12.3. Product Benchmarking
  - 8.5.12.4. Strategic initiatives
- 8.5.13. Neuropace Inc.
  - 8.5.13.1. Company overview
  - 8.5.13.2. Financial performance
  - 8.5.13.3. Product Benchmarking
  - 8.5.13.4. Strategic initiatives
- 8.5.14. Mainstay Medical
  - 8.5.14.1. Company overview
  - 8.5.14.2. Financial performance
  - 8.5.14.3. Product Benchmarking
  - 8.5.14.4. Strategic initiatives
- 8.5.15. Saluda Medical Pty Ltd
  - 8.5.15.1. Company overview
  - 8.5.15.2. Financial performance
  - 8.5.15.3. Product Benchmarking
  - 8.5.15.4. Strategic initiatives
- 8.5.16. Biotronik
  - 8.5.16.1. Company overview
  - 8.5.16.2. Financial performance
  - 8.5.16.3. Product Benchmarking
  - 8.5.16.4. Strategic initiatives
- 8.5.17. electroCore, Inc.
  - 8.5.17.1. Company overview
  - 8.5.17.2. Financial performance
  - 8.5.17.3. Product Benchmarking
  - 8.5.17.4. Strategic initiatives
- 8.5.18. MicroTransponder Inc.
  - 8.5.18.1. Company overview
  - 8.5.18.2. Financial performance
  - 8.5.18.3. Product Benchmarking
  - 8.5.18.4. Strategic initiatives
- 8.5.19. tVNS Technologies GmbH
  - 8.5.19.1. Company overview
  - 8.5.19.2. Financial performance
  - 8.5.19.3. Product Benchmarking
  - 8.5.19.4. Strategic initiatives
- 8.5.20. Laborie
  - 8.5.20.1. Company overview
  - 8.5.20.2. Financial performance
  - 8.5.20.3. Product Benchmarking
  - 8.5.20.4. Strategic initiatives

한글목차

신경조절 기기 시장 개요

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 신경조절 기기 시장 변수, 동향, 범위

제4장 신경조절 기기 시장 : 제품별, 추정·동향 분석

제5장 신경조절 기기 시장 : 용도별, 추정·동향 분석

제6장 신경조절 기기 시장 : 최종 용도별, 추정·동향 분석

제7장 신경조절 기기 시장 : 제품, 용도, 최종 용도별 지역별, 추정·동향 분석